Vertex Pharmaceuticals: Opportunities And Dangers

7/25/18

By William Meyers, SeekingAlpha

Summary

Vertex has a high P/E ratio of 214, so is priced to perfection.

Vertex saw a big dip in 2016 after Incivek revenue dropped.

Successful expansion in and beyond cystic fibrosis should keep earnings growing.

Vertex Pharmaceuticals (VRTX) is a successful large cap ($46 billion) pharmaceutical company specializing in the treatment of CF (cystic fibrosis) but aiming at a broader array of disease targets.

Given its ambitions, the current stock price is not unreasonable, presuming continued future successes bring new drugs to market over the next decade. Potential new investors, however, should be aware of how much future success is priced into the stock already, as it may be priced to perfection.

With Vertex about to release Q2 results on Wednesday, July 25, it is a good time to review the situation.

READ FULL ARTICLE HERE